Latest period
$5.13B
YoY change
+17.1%
5Y CAGR
+7.8%
Peak year (2025)
$4.97B
Latest annual
$4.97B
Total Assets history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $4.97B
Total Assets growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: +17.1%
Total Assets history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $4.97B | +17.1% | +$726.35M | ||
| 2024 | $4.24B | +10.7% | +$410.10M | ||
| 2023 | $3.83B | +8.0% | +$283.52M | ||
| 2022 | $3.55B | -2.7% | −$96.94M | ||
| 2021 | $3.64B | +6.9% | +$236.24M | ||
| 2020 | $3.41B | +42.2% | +$1.01B | ||
| 2019 | $2.40B | +52.1% | +$820.33M | ||
| 2018 | $1.57B | -21.1% | −$419.93M | ||
| 2017 | $1.99B | +58.0% | +$731.92M | ||
| 2016 | $1.26B | -8.9% | −$123.70M | ||
| 2015 | $1.39B | +28.4% | +$306.92M | ||
| 2014 | $1.08B | +156.7% | +$659.07M | ||
| 2013 | $420.53M | +46.3% | +$133.01M | ||
| 2012 | $287.52M | +2.0% | +$5.60M | ||
| 2011 | $281.92M | -28.3% | −$111.35M | ||
| 2010 | $393.26M | -18.3% | −$88.12M | ||
| 2009 | $481.38M | -13.2% | −$73.29M | ||
| 2008 | $554.68M | +12.3% | +$60.88M | ||
| 2007 | $493.79M | +105.7% | +$253.78M | ||
| 2006 | $240.01M | +144.0% | +$141.66M | ||
| 2005 | $98.35M | +48.8% | +$32.24M | ||
| 2004 | $66.11M | +87.9% | +$30.92M | ||
| 2003 | $35.18M | +118.4% | +$19.07M | ||
| 2002 | $16.11M | — | — |
- 2025$4.97B+17.1%
- 2024$4.24B+10.7%
- 2023$3.83B+8.0%
- 2022$3.55B-2.7%
- 2021$3.64B+6.9%
- 2020$3.41B+42.2%
- 2019$2.40B+52.1%
- 2018$1.57B-21.1%
- 2017$1.99B+58.0%
- 2016$1.26B-8.9%
- 2015$1.39B+28.4%
- 2014$1.08B+156.7%
- 2013$420.53M+46.3%
- 2012$287.52M+2.0%
- 2011$281.92M-28.3%
- 2010$393.26M-18.3%
- 2009$481.38M-13.2%
- 2008$554.68M+12.3%
- 2007$493.79M+105.7%
- 2006$240.01M+144.0%
- 2005$98.35M+48.8%
- 2004$66.11M+87.9%
- 2003$35.18M+118.4%
- 2002$16.11M—
Total Assets values are taken from Alnylam Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Assets at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported total assets is $5.13B. Total assets sum everything the company reports owning at the end of each reporting period — cash, receivables, inventory, property, plant, equipment, intangibles, and other holdings — as filed on the balance sheet. Compare with total liabilities and total equity for the capital-structure picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Alnylam Pharmaceuticals (ALNY) total assets totalled $4.97B – grew 17.1% year-over-year.
Through 2020–2025 (5 years), Alnylam Pharmaceuticals total assets delivered a +7.8% annualised rate; sustaining 3 straight years of year-over-year growth.
$4.97B stands as the all-time-high annual total assets, posted in 2025, against a low of $16.11M during 2002.
Alnylam Pharmaceuticals Total Assets by Year
Alnylam Pharmaceuticals Total Assets 2025: $4.97B
2025's total assets for Alnylam Pharmaceuticals came in at $4.97B, grew 17.1% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Total Assets 2024: $4.24B
Alnylam Pharmaceuticals posted total assets of $4.24B in 2024, grew 10.7% from 2023.
Alnylam Pharmaceuticals Total Assets 2023: $3.83B
In 2023, Alnylam Pharmaceuticals reported total assets of $3.83B, grew 8.0% from 2022.
Alnylam Pharmaceuticals Total Assets 2022: $3.55B
Alnylam Pharmaceuticals total assets in 2022 was $3.55B, edged down 2.7% below 2021.
Alnylam Pharmaceuticals Total Assets 2021: $3.64B
Alnylam Pharmaceuticals total assets in 2021 was $3.64B.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Total Assets
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest total assets
| $309.58B | |
| $199.21B | |
| $136.87B | |
| $133.96B | |
| $114.07B | |
| $112.48B | |
| $90.59B | |
| $85.37B |
- $309.58B
- $199.21B
- $136.87B
- $133.96B
- $114.07B
- $112.48B
- $90.59B
- $85.37B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation